Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical and immunological studies in advanced cancer patients sequentially treated with anti CD3 monoclonal antibody (OKT3) and interleukin-2.

Leukemia & lymphoma - 1 Apr 1996

Borrione P, Montacchini L, Beggiato E, Pileri A, Bianchi A, Massaia M

Abstract excerpt

CD3 engagement has been used as a surrogate for antigen-specific stimulation to trigger T cell effector functions. Exogenous IL-2 has been used to prolong and amplify CD3-induced T cell activation. Previous studies have been shown that CD3 reactivity is increased in cancer patients with preactivated (> 10% HLA-DR+) T cells in the peripheral blood. In this study, we report 9 courses of a single infusion of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to CD3 Complex

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to HLA-DR Antigens

Share to Interleukin-2

Share to Leukocyte Count

Share to Lymphocyte Activation

Share to Melanoma

Share to Phenotype

Source

Identifiers

PMID: 8726415
DOI: 10.3109/10428199209067615

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical and immunological studies in advanced cancer patients sequentially treated with anti CD3 monoclonal antibody (OKT3) and interleukin-2.PMID 8726415Read ↗

Preclinical studies for adoptive immunotherapy in bone marrow transplantation. Generation of anti-CD3 activated cytotoxic T cells from normal donors and autologous bone marrow transplant candidates.Semantic proximity Read ↗

Solid-phase anti-CD3 antibody activation of murine tumor-infiltrating lymphocytes.Semantic proximity Read ↗

Phenotypic and functional modulation of interleukin-2-activated peripheral blood mononuclear cells by anti-CD3 and anti-CD28 antibody.Semantic proximity Read ↗

Tumour-infiltrating lymphocytes in primary melanoma: functional consequences of differential IL-2 receptor expression.Semantic proximity Read ↗

Further characterization of cytotoxic T cells generated by short-term culture of human peripheral blood lymphocytes with interleukin-2 and anti-CD3 mAb.Semantic proximity Read ↗

Anti-CD3 monoclonal antibody-mediated cytotoxicity occurs through an interleukin-2-independent pathway in CD3+ large granular lymphocytes.Semantic proximity Read ↗

Clonal analysis of tumor-infiltrating lymphocytes from human primary and metastatic liver tumors.Semantic proximity Read ↗

Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade.Semantic proximity Read ↗

A pilot study of intralymphatic interleukin-2. I. Cytotoxic and surface marker changes of peripheral blood lymphocytes.Semantic proximity Read ↗

Multiple infusions of CD20-targeted T cells and low-dose IL-2 after SCT for high-risk non-Hodgkin's lymphoma: a pilot study.Semantic proximity Read ↗

Different activation states of human lymphocytes after antibody-mediated stimulation via CD3 and the alpha/beta T-cell receptor.Semantic proximity Read ↗

Expanded tumor-reactive CD4+ T-cell responses to human cancers induced by secondary anti-CD3/anti-CD28 activation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.